Patients often see a dramatic drop in appetite as proof that a weight loss treatment is “working.” They eat less, feel less hungry, and may initially lose weight quickly. The danger is that appetite suppression can hide deeper nutritional gaps forming beneath the surface, leaving the body with too little protein, fibre, micronutrients, hydration, and energy to preserve muscle mass and normal function.
This challenge has become more visible recently with the growing use of injectable weight-management medicines, including glucagon-like peptide-1 (GLP-1) treatments. Used correctly, these medicines can be clinically effective tools for appropriate patients, but many patients still treat nutrition as something detached from the medicine.
According to Dr Gerhard Vosloo, Founder and Head Consulting Practitioner of Dr GL Vosloo Medical Practice, managed by BioWell, “Appetite suppression changes the amount a patient can comfortably eat, which means the treatment plan has to become more precise. Patients need guidance on how to structure intake, when to adjust the plan, and how to respond when appetite drops too far. Physician oversight is critical here because the decision to use a GLP-1 cannot be separated from the responsibility to manage what happens after appetite adjusts.”
Understanding the changes to your nutritional needs
GLP-1 therapies act on gut and brain-based appetite regulation pathways, reducing hunger signals and increasing satiety. While this mechanism supports weight loss, it also changes how patients make everyday food decisions. “Once the ‘food noise’ quiets, patients can no longer rely only on appetite to guide when and how they eat. The treatment plan must give them a structure that still works when hunger is no longer the main prompt. Patients may need to move from hunger-led eating to planned eating during treatment,” he says.
A doctor-led metabolic management plan must provide clear nutritional priorities at each stage of treatment, rather than relying on generic diet advice. If intake falls too far, the treating physician may need to reassess the pace of treatment and consider additional nutritional support or supplementation where clinically appropriate.
Steps to take to align nutrition with treatment
Sustainable outcomes in GLP-1 therapy often require deep behavioural change that matches the way treatment alters appetite and daily eating patterns. Dr Vosloo identifies five key areas of nutrition planning that patients using pharmaceutical therapy under medical supervision should focus on:
- Prioritise protein within the meals you can tolerate
Reduced appetite can leave patients with fewer meaningful eating opportunities in a day. Protein therefore must be planned into the meals a patient can realistically manage, rather than treated as something to make up later.
- Keep fibre practical when food volume drops
Patients may need more deliberate food choices when smaller meals reduce their usual fibre intake. Fibre should be included deliberately where tolerated, with constipation, bloating, or changes in bowel habits raised during follow-up rather than ignored.
- Protect micronutrient intake through food quality first
A lower appetite can narrow the range of foods patients eat during treatment. Meals should therefore be planned around food quality and variety before supplementation is considered, with supplements used only where they are clinically appropriate.
- Build eating patterns that no longer depend on hunger
Because patients using GLP-1 therapy may not feel the same natural prompts to eat, meal timing, hydration, and food choices should be scheduled deliberately rather than left to appetite alone.
- Use follow-ups to keep the programme aligned
Nutritional support should change as the patient changes. Appetite, food tolerance, side effects, energy, and general functioning should be reviewed throughout treatment so the doctor can adjust the programme where needed.
“Nutrition and exercise are the undeniable core of any weight and metabolic management programme. Pharmaceutical support, such as GLP-1 treatment, must only be considered following a proper clinical assessment that confirms a genuine medical need, screens for risk, and establishes that the patient is entering treatment with the structure needed to use it responsibly. The medicine can support the process, but it cannot replace the fundamentals that determine whether the outcome will hold,” concludes Dr Vosloo.
This information is for educational purposes only and does not replace professional medical advice. Treatment decisions must be made in consultation with a qualified healthcare provider.
About Dr GL Vosloo Medical Practice and BioWell
Dr GL Vosloo Medical Practice is a registered medical practice managed by BioWell and led by Dr Vosloo, a South African Sports, Exercise, and Lifestyle Physician. The practice operates within the regulatory framework of the HPCSA. All clinical decisions are made by registered medical professionals, and all prescriptions are issued in accordance with applicable medical regulations.
BioWell is a healthcare platform that supports the delivery of structured metabolic health programmes through patient coordination, clinical workflow management, and programme administration. BioWell does not prescribe medication or provide medical advice. All medical treatment is conducted under the supervision of Dr GL Vosloo Medical Practice. Consultations are conducted via the BioWell patient portal at www.bio-well.co.za or by contacting info@bio-well.co.za.
